Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in TEM.

← Back to Free Index

TEM

Analysis as of: 2026-09-28

Tempus AI, Inc.

Tempus AI sells molecular diagnostics, clinical workflow software, and governed data tools that help physicians and drug developers use patient data in precision medicine.

ai enterprise healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Data rights deepen while reimbursement still decides

This is not a standard lab growth story. The five-year upside depends on converting diagnostic scale into recurring data, monitoring, and workflow revenue faster than regulation and integration slow it.

Analysis

Thesis

Tempus can compound faster than ordinary diagnostics because each added test, workflow deployment, and monitoring program enlarges a governed healthcare data asset that can be monetized again through research, software, and clinical products; if reimbursement and integration gates clear, revenue quality should improve enough to roughly double enterprise value by 2031.

Last Economy Alignment

Cheaper AI raises the value of Tempus' permissioned clinical data and regulated workflows more than it threatens its software layer, but reimbursement and privacy gates still cap compounding.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.3x (from 5 most recent analyses)

Reasoning

The upside case is still a quality-of-revenue story. Tempus already has real demand, but the five-year win comes from shifting mix toward recurring data, workflow, and monitoring revenue while improving diagnostic pricing and reimbursement. Because today’s valuation already assumes meaningful success, the realistic outcome is a strong double rather than a moonshot.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not product relevance but economic conversion. Tempus has real assets in data rights, diagnostics, and workflow distribution, yet the five-year rerating still depends on a tight sequence: close and integrate Personalis, expand monitoring adoption, win regulatory and reimbursement steps, and turn large data bookings into repeatable recognized revenue. If those gates slip, valuation can compress toward diagnostics peers faster than revenue grows.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On September 28, 2026, Tempus announced FDA clearance for ECG-MR, its fourth cleared ECG-AI product; this modestly strengthens the regulated software and cardiology adjacency story.
On September 21, 2026, Tempus extended its Recursion data partnership through November 2029 and converted a larger discretionary structure into smaller committed payments, improving visibility but lowering near-term upside rate.
No late-September filing resolved Personalis closing timing or the liquid-biopsy approval timetable, so the main value gates remain execution and regulation rather than new narrative expansion.

Thesis update

No material thesis change. Recent disclosures mostly reinforce the same core view: governed data rights are the durable asset, while regulation and commercialization still determine how much of that value Tempus captures.

Forecast update

No bucket change. I am slightly more focused on certainty versus upside magnitude because recent partnership news de-risks revenue visibility more than it expands the eventual profit pool.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.70

They control permissioned patient data and the workflow pipes that make it useful, so cheaper AI can make their owned data more valuable instead of making them obsolete. The risk is that regulators, payers, or larger healthcare platforms slow the move from smart tools to paid clinical action.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$68.18

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research